Low-Dose Zoladex Won’t Be Available in Australia From November. What Might that Mean for You?

Why It Matters

The delisting removes a widely used, PBS‑subsidised hormone‑suppression option, potentially raising out‑of‑pocket costs and forcing clinicians to adjust treatment pathways.

Key Takeaways

• AstraZeneca delists 3.6 mg Zoladex from PBS effective 1 Nov 2026.
• Low‑dose Zoladex served ~100,000 Australian scripts in 2025.
• High‑dose 10.8 mg implant remains and may gain PBS subsidy.
• Patients can switch to alternative hormone therapies or other oncology regimens.
• Decision driven by commercial, not safety, considerations.

Pulse Analysis

Zoladex (goserelin) has been a cornerstone of hormone‑suppression therapy in Australia for decades, delivering a monthly 3.6 mg implant that lowers testosterone or estrogen levels. Its clinical utility spans androgen‑deprivation therapy for prostate cancer, estrogen‑blocking treatment for pre‑menopausal ER‑positive breast cancer, and symptom control in endometriosis. In 2025 the low‑dose product generated close to 100,000 PBS prescriptions, reflecting its entrenched role in the oncology and women’s health landscapes.

AstraZeneca’s decision to withdraw the low‑dose formulation is framed as a commercial move rather than a safety issue. The company cites limited demand—Australia represents roughly 2 % of global medicine consumption—and the cost efficiencies of consolidating production around the higher‑dose 10.8 mg implant, which requires quarterly administration. By eliminating the monthly product, AstraZeneca can reallocate manufacturing capacity and potentially accelerate development of newer agents. For the PBS, the removal means the subsidy for a widely used, low‑cost option disappears, likely shifting some patients to private pay or alternative regimens.

Clinicians now face a transition period until November 2026 to restructure treatment plans. The higher‑dose Zoladex may become PBS‑listed, offering a quarterly alternative, but not all patients can tolerate the larger dose. Oncology guidelines already list numerous hormone‑therapy combos and chemotherapy protocols that omit Zoladex, providing viable substitutes for prostate and breast cancers. Women with endometriosis can turn to contraceptive‑based progestogens or other hormonal modulators. Prompt consultation with oncologists or pharmacists is essential to avoid treatment gaps and manage any additional financial burden.